A director at Hubbell Inc sold/sold after exercising options 1,942 shares at 401.344USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...
A director at Onemain Holdings Inc sold 7,500 shares at 50.631USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
WEST READING, Pa.--(BUSINESS WIRE)-- Customers Bank, the $22 billion asset subsidiary of Customers Bancorp (NYSE:CUBI), is furthering its commitment as a leading partner to the venture banking and startup communities through its sixth overall venture fund investment. After submitting a winning bid to the Federal Deposit Insurance Corporation, Customers Bank purchased a minority limited partnership interest for $5 million in the fund at an approximate 70% discount to the original cost of investment. “This investment further solidifies Customers Bank’s position as a leading partner to the ve...
Jackson Walker selects Intapp to advance timekeeping practices Am Law 200 firm using Intapp Time to facilitate compliant and accurate time capture PALO ALTO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: INTA), a leading global provider of AI-powered solutions for professionals at advisory, capital markets, and legal firms, announces that Am Law 200 firm selected to advance the firm’s timekeeping practices. The software uses Applied AI to automate time capture and compliance with client requirements, leading to improved client satisfaction. Leading change "When evaluating new ...
Google kicked off its I/O event with a keynote address earlier today. In this brief note, we discuss stock implications and new announcements, including: 1. Update on the GOOGL Catalyst Path & AI Vibe Check 2. AI Overviews rolling out across Search in the US, to 1B users by year-end. 3. Project Astra: GOOGL’s universal AI agent spans across product features. 4. 1M-token Gemini context-window rolling out, 2M-token context moves to private preview. 5. TPU v6: Trillium appears focused on inference ...
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights – CONNECT1-EDO51 trial preliminary data from 5mg/kg dose cohort expected mid-2024 – – FREEDOM1-DM1 trial preliminary data from at least 5mg/kg dose cohort expected second half 2024 – – Net proceeds of $86.3 million from common stock offerings extending cash runway into 2026 – BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neur...
The next two weeks include three of GOOGL’s most important events of the year: • Google I/O for developers and new consumer products today. • YouTube Brandcast for brand advertising on Wednesday. • Google Marketing Live (GML) for performance advertising next Tues May 21st
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date Updated data to be presented at the European Hematology Association (EHA) Annual Meeting KT-333 Phase 1 study ongoing with additional data expected in the second half of 2024 WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.